First U.S. CRT Device with A-Fib Feature
St. Jude Medical Inc.’s new cardiac rhythm management device is designed to help physicians manage heart failure (HF) patients, including patients who have or may develop atrial fibrillation (AF).
The Atlas II HF CRT-D (cardiac resynchronization therapy defibrillator) is the first U.S. heart failure device to offer the AF Suppression proprietary algorithm that helps maintain control of the heart's atrial rhythm by pacing slightly faster than the patient's natural heart rate. The AF Suppression algorithm has been clinically proven to reduce the AF burden (the percentage of days with AF symptoms) in previous studies.
Atlas II HF CRT-D also offers the company's QuickOpt timing cycle optimization feature, a programmer-based optimization for people with CRT-D devices and traditional ICDs that helps physicians quickly program the device's timing so it delivers optimal therapy to patients.
Other features of the Atlas II HF CRT-D are designed to help physicians manage difficult-to-treat conditions:
More like this
- St Jude Receives FDA Clearance for First U.S. CRT Device with A-Fib Feature
- ACC: St. Jude Receives FDA Clearance for First U.S. CRT Device with A-Fib Feature
- St. Jude Launches QuickOpt Timing Cycle Optimization for Defibrillators in Japan
- St. Jude Gets Japanese Approval for Heart Failure Treatment Products
- St. Jude's CRT-D, ICD Extend their Lead with Durata